β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of α-amino substituents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1140-1145

  Yang, Shyh Ming ^a   Scannevin, Robert H ^a   Wang, Bingbing ^a   Burke, Sharon L ^a   Huang, Zhihong ^a   Karnachi, Prabha ^a   Wilson, Lawrence J ^a   Rhodes, Kenneth J ^a   Lagu, Bharat ^a   Murray, William V ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Gelatinase; Hydroxamate; Matrix metalloproteinase; MMP inhibitor; Stroke

Indexed keywords

GELATINASE; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; ISCHEMIA; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; RAT;

AMINO ACIDS; ANIMALS; BRAIN EDEMA; DISEASE MODELS, ANIMAL; DRUG DESIGN; GELATINASES; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROSOMES, LIVER; MIDDLE CEREBRAL ARTERY; MOLECULAR STRUCTURE; PYRAZINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

RATTUS;

EID: 38749108827     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.129     Document Type: Article

References (30)

1. Recent reviews, see:. Fingleton B. Curr. Pharm. Des. 13 (2007) 333
2. Fingleton B. Exp. Opin. Ther. Targets 7 (2003) 385
3. Vihinen P., Ala-aho R., and Kähäri V.-M. Curr. Cancer Drug Targets 5 (2005) 203
4. George S.J. Exp. Opin. Invest. Drugs 9 (2000) 993
5. Yong V.W. Exp. Opin. Invest. Drugs 8 (1999) 255
6. Yong V.W., Power C., Forsyth P., and Edwards D.R. Nat. Rev. Neurosci. 2 (2001) 502
7. Clarke A.W., Krekoski C.A., Bou S.-S., Chapman K.R., and Edwards D.R. Neurosci. Lett. 238 (1997) 53
8. Joan Montaner J., Alvarez-Sabín J., Molina C., Anglés A., Abilleira S., Arenillas J., González M.A., and Monasterio J. Stroke 32 (2001) 1759
9. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., and Barone F.C. Stroke 29 (1998) 1020
10. Asahi M., Wang X., Mori T., Sumii T., Jung J.C., Moskowitz M.A., Fini M.E., and Lo E.H. J. Neurosci. 21 (2001) 7724
11. Jiang X.-F., Namura S., and Nagata I. Neurosci. Lett. 35 (2001) 41
12. Lapchak P.A., Chapman D.F., and Zivin J.A. Stroke 31 (2000) 3034
13. Kim S.-H., Pudzianowski A.T., Leavitt K.J., Barbosa J., McDonnell P.A., Metzler W.J., Rankin B.M., Liu R., Vaccaro W., and Pitts W. Bioorg. Med. Chem. Lett. 15 (2005) 1101
14. Cherney R.J., Mo R., Meyer D.T., Hardman K.D., Liu R.-Q., Covington M.B., Qian M., Wasserman Z.R., Christ D.D., Trzaskos J.M., Newton R.C., and Decicco C.P. J. Med. Chem. 47 (2004) 2981
15. Yang S.-M., Scannevin R.H., Wang B., Burke S.L., Wilson L.J., Karnachi P., Rhodes K.J., Lagu B., and Murray W.V. Bioorg. Med. Chem. Lett. 18 (2008) 1135
16. α-Amino-β-sulfone hydroxamates as potent MMP-13 inhibitors have been reported recently, see:. Becker D.P., Barta T.E., Bedell L., DeCrescenzo G., Freskos J., Getman D.P., Hockerman S.L., Li M., Mehta P., Mischke B., Munie G.E., Swearingen C., and Villamil C.I. Bioorg. Med. Chem. Lett. 11 (2001) 2719
17. Becker D.P., DeCrescenzo G., Freskos J., Getman D.P., Hockerman S.L., Li M., Mehta P., Munie G.E., and Swearingen C. Bioorg. Med. Chem. Lett. 11 (2001) 2723
18. Huang Z., Huang P.L., Panahian N., Dalkara T., Fishman M.C., and Moskowitz M.A. Science 265 (1994) 1883
19. Longa E.Z., Weinstein P.R., Carlson S., and Cummins R. Stroke 20 (1989) 84
20. Hara H., Huang P.L., Panahian N., Fishman M.C., and Moskowitz M.A. J. Cereb. Blood Flow Metab. 16 (1996) 605
21. Yang S.-M., and Murray W.V. Tetrahedron Lett. (2008) 10.1016/j.tetlet.2007.11.184
22. Albanese D., Landini D., Lupi V., and Penso M. Ind. Eng. Chem. Res. 42 (2003) 680 and the references cited therein
23. Kogan T.P., Somers T.C., and Venuti M.C. Tetrahedron 46 (1990) 6623
24. Uenishi J., Hamada M., Aburatani S., Matsui K., Yonemitsu O., and Tsukube H. J. Org. Chem. 69 (2004) 6781
25. The present skeleton, indeed, tolerates well small α-substituents such as OH, Me, and OMe. The influence on potency by the α-chirality is minimal, see Ref. 7.
26. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., Zhu L., Hu S., Melton R.A., Fryer L., Goldberg R.L., Doughty J.R., Spirito S., Blancuzzi V., Wilson D., O'Byrne E.M., Ganu V., and Parker D.T. J. Med. Chem. 40 (1997) 2525
27. Reiter L.A., Robinson R.P., McClure K.F., Jones C.S., Reese M.R., Mitchell P.G., Otterness I.G., Bliven M.L., Liras J., Cortina S.R., Donahue K.M., Eskra J.D., Griffiths R.J., Lame M.E., Lopez-Anaya A., Martinelli G.J., McGahee S.M., Yocum S.A., Lopresti-Morrow L.L., Tobiassen L.M., and Vaughn-Bowser M.L. Bioorg. Med. Chem. Lett. 14 (2004) 3389
28. Noe M.C., Natarajan V., Snow S.L., Mitchell P.G., Lopresti-Morrow L., Reeves L.M., Yocum S.A., Carty T.J., Barberia J.A., Sweeney F.J., Liras J.L., Vaughn M., Hardink J.R., Hawkins J.M., and Tokar C. Bioorg. Med. Chem. Lett. 15 (2005) 2808
29. 50 > 10 μM).
30. 2O) both as a bolus and through minipump infusion. Twenty-four hours after onset of ischemia animals were euthanized and the brain was quickly removed to evaluate water content by the wet/dry method. The water content in two hemispheres of the brain tissue was calculated as follows: 100 × [(wet weight - dry weight)/wet weight] (%). The percentage increase of the brain water content after ischemia was calculated by the difference in water content between the ischemic ipsilateral and non-ischemic contralateral hemispheres. See: Yanamoto, H.; Nagata, I.; Niitsu, Y.; Xue, J. H.; Zhang, Z.; Kikuchi, H. Exp. Neurol. 2003, 182, 261.